# Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

> **NCT06634927** · PHASE1 · COMPLETED · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 68 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Ozempic®
- **DRUG:** HDG1901

## Key facts

- **NCT ID:** NCT06634927
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-22
- **Primary completion:** 2024-11-14
- **Final completion:** 2025-02-12
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06634927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06634927, "Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06634927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*